Regeneron announces new u.s. government agreement to purchase additional doses of regen-cov™ (casirivimab and imdevimab) antibody cocktail

Tarrytown, n.y., sept. 14, 2021 /prnewswire/ -- new agreement for 1.4 million doses of regen-cov, brings total purchased by the u.s. government to nearly 3 million doses regen-cov currently authorized to treat certain infected patients to reduce risk of hospitalization or death from covid-19, and for post-exposure prophylaxis for close contacts of infected individuals regeneron pharmaceuticals, inc. (nasdaq: regn) today announced that the u.s. department of health and human services (hhs) and the department of defense (dod) will purchase 1.4 million additional doses of regen-cov (casirivimab and imdevimab).
REGN Ratings Summary
REGN Quant Ranking